FDA Class II Recall: Par Sterile Products' Vasostrict Superpotency Poses Supply Chain Risk
Par Sterile Products LLC has initiated a nationwide Class II recall for Vasostrict (vasopressin) injection due to superpotency. This event, impacting 1,721 cartons, signals critical quality control failures in manufacturing stability testing. Procurement and supply chain leaders must assess immediate inventory, potential shortages, and the broader implications for injectable drug sourcing and patient safety.
FDA Initiates Class II Recall for Par Sterile Products' Vasostrict Due to Superpotency
The U.S. Food and Drug Administration (FDA) has classified a voluntary recall initiated by Par Sterile Products LLC for its Vasostrict (vasopressin) Injection as Class II. This action, identified under recall number D-0232-2024, addresses a critical quality deviation where the drug product was found to be superpotent. Specifically, assay results from both the 3-month and 6-month stability intervals exceeded the established upper specification limit, indicating a higher concentration of the active ingredient than intended. This recall impacts 1,721 cartons of Vasostrict, distributed nationwide across the USA, from Lot # 66702 with an expiration date of February 2025. The product is packaged as 20 units per 100 mL (0.2 units per mL) in 100 mL x 10 Single Dose Vials, ready for intravenous infusion. For procurement directors and supply chain VPs, this means an immediate need to verify inventory against the specified lot number and ensure proper quarantine and return procedures are in place. The superpotency issue could lead to adverse patient outcomes, elevating the risk profile for healthcare providers utilizing this product. This event underscores the imperative for robust quality control throughout the drug product lifecycle, from manufacturing at facilities like Par Sterile Products LLC in Rochester, MI, to distribution by entities such as Par Pharmaceutical.
Commercial Implications of Vasopressin Superpotency for US Healthcare Supply Chains
The recall of superpotent Vasostrict (vasopressin) by Par Sterile Products LLC presents significant commercial and operational challenges for the global chemical and life sciences industry, particularly within the United States. Vasopressin, marketed under the brand name Vasostrict (NDA204485), is a critical care medication used in various clinical settings. A Class II recall for superpotency means that the use of the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. For procurement directors, this necessitates an immediate assessment of current stock levels and the identification of alternative sourcing strategies for vasopressin to prevent potential supply disruptions. The affected product, with NDC 42023-237-10, was distributed nationwide, indicating a broad impact on hospital pharmacies and healthcare systems. Supply chain VPs must evaluate their resilience plans, considering the time required to qualify new suppliers or secure alternative formulations of vasopressin. Business development executives should monitor market dynamics closely, as such recalls can shift market share and create opportunities for competitors with compliant products. The financial implications extend beyond the direct cost of returned goods, encompassing potential reputational damage and the administrative burden of managing a recall of this scale.
Navigating Regulatory Scrutiny: Broader Industry Context for Drug Recalls
The Class II recall of Vasostrict by Par Sterile Products LLC occurs within a broader landscape of intensified regulatory scrutiny over pharmaceutical manufacturing and quality control. While this specific event pertains to superpotency, it aligns with a persistent trend of recalls across the industry. Recent parallel events highlight the diverse nature of these challenges: Cardinal Health Inc. faced a Class II recall for XIGDUO XR due to storage temperature excursions, and Lupin Pharmaceuticals initiated a Class II recall for Lisinopril Tablets over dose mix-ups. Amneal Pharmaceuticals also recalled Nizatidine Oral Solution due to NDMA contamination and CGMP deviations. These incidents, though unrelated to Par Sterile Products LLC's history, collectively underscore the FDA's unwavering focus on product quality and patient safety. For regulatory affairs heads, this environment demands proactive compliance strategies, robust quality management systems, and continuous monitoring of stability data. The expectation is that manufacturers, including Par Sterile Products LLC operating from Rochester, MI, maintain strict adherence to Good Manufacturing Practices (GMP) to prevent deviations that lead to recalls. Failure to meet these standards can result in significant regulatory actions, impacting market access and operational continuity for any pharmaceutical entity.
Strategic Response and Future Outlook for Par Sterile Products LLC
As the recall of Vasostrict (vasopressin) remains ongoing, Par Sterile Products LLC faces a critical period of remediation and intensified regulatory oversight. The firm-initiated, voluntary nature of the recall indicates their acknowledgment of the superpotency issue and proactive steps to remove the affected Lot # 66702 from the market. However, the FDA will closely monitor the effectiveness of this recall and the company's corrective and preventive actions (CAPA) plan. Regulatory affairs heads must ensure a comprehensive investigation into the root cause of the stability failure, which led to the assay exceeding upper specification limits at the 3-month and 6-month intervals. This includes a thorough review of manufacturing processes, analytical methods, and quality control systems at their Rochester, MI facility. For business development executives and procurement directors, understanding the speed and efficacy of Par Sterile Products LLC's remediation efforts is crucial for assessing future supply reliability. Delays in addressing the underlying quality issues could lead to further regulatory actions, including potential Warning Letters or even import alerts if international distribution were involved. The company's ability to demonstrate sustained compliance will be key to rebuilding confidence among its customers and the broader healthcare community, ensuring the continued availability of essential medications like vasopressin.